Medtronic (MDT) Tops Q3 EPS by 3c; Bumps Guidance Higher

Medtronic (NYSE: MDT) reported Q3 EPS of $1.30, $0.03 better than the analyst estimate of $1.27. Revenue for the quarter came in at $7.7 billion versus the consensus estimate of $7.54 billion.

GUIDANCE:

Medtronic raises FY2023 EPS of $5.28-$5.30, versus the prior of $5.25-$5.30 and the consensus of $5.27. The company expects fourth quarter organic revenue growth of 4.5% to 5.0%.

For earnings history and earnings-related data on Medtronic (MDT) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Morgan Stanley Downgrades Melco Resorts (MLCO) to Equalweight
• Pfizer reaffirms 2026 guidance after CFO transition news